glp-1 study Cardiovascular and mortality outcomes with receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort | Diabetologia GLP-1 Medications Get at the

This should give it ample runway over the next several quarters as it continues to develop aleniglipron, with the drug candidate moving toward a critical Phase 3 trial.

If the medication is approved, it will join a growing market of weight-loss medications that includes Lilly's existing anti-obesity medications Zepbound and the weight-loss pill Foundayo

Cardiovasc Diabetol 2011

What You Can Expect at MediPlan Diet Services We dont just prescribe and send you on your way

Studies are currently examining the role of GLP-1s in conditions such as heart failure with preserved ejection fraction, metabolic dysfunction-associated steatohepatitis, Alzheimers disease, Parkinsons disease, peripheral artery disease, diabetic kidney disease and cancer, and other pharmaceutical manufacturers are expected to apply for similar GLP-1 label expansions in the future

These testimonials are brand-published individual experiences